Takeda's Zasocitinib Outperforms Rival in Psoriasis Trials, Boosting…

Event summary

Takeda's zasocitinib demonstrated superior efficacy compared to deucravacitinib in Phase 3 head-to-head trials, with 36.5% of patients achieving complete skin clearance (PASI 100) at week 16 versus 13.9% for deucravacitinib.
Zasocitinib showed rapid and durable skin clearance, with up to 93% of responders maintaining results through week 52 in long-term data.
The drug was generally well-tolerated, with no new safety signals identified, reinforcing its potential as a convenient once-daily oral treatment.
Takeda plans to submit additional regulatory applications globally following positive Phase 3 results.

The big picture

Takeda's zasocitinib represents a next-generation oral treatment for moderate-to-severe plaque psoriasis, leveraging highly selective TYK2 inhibition. The positive Phase 3 results position it as a potential market leader in a space dominated by injectables and biologics. The drug's rapid and durable efficacy, combined with a favorable safety profile, could reshape treatment expectations for psoriasis patients and clinicians alike.

What we're watching

Regulatory Approval: Whether the U.S. FDA and European EMA will grant approval for zasocitinib based on the Phase 3 data, potentially expanding Takeda's portfolio in psoriasis treatment.
Market Differentiation: How zasocitinib's superior efficacy and once-daily convenience will position it against existing oral and injectable treatments in the psoriasis market.
Pipeline Expansion: The progress of zasocitinib in other indications, including psoriatic arthritis, Crohn’s disease, and hidradenitis suppurativa, which could broaden its commercial potential.